ALK and neoplasm: Most of the baseline clinical characteristics including age, sex, ECOG PS, histology, EGFR and ALK mutation status, PD‐L1 tumor proportion score, CRT protocol and timing of durvalumab initiation were similar between the high and low NLR groups (Table 3).